Literature DB >> 7624989

Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.

D Golijanin1, Y Sherman, A Shapiro, D Pode.   

Abstract

OBJECTIVES: A study was made to determine the sensitivity and specificity of immunostaining of the Lewis X antigen in exfoliated urothelial cells from voided urine, for the detection and surveillance of bladder tumors.
METHODS: Three consecutive voided urine specimens were obtained from 101 patients, 78 of whom were under surveillance because of a history of bladder tumors, and 23 were being evaluated because of hematuria or irritative urinary symptoms. Indirect immunoperoxidase staining of two urine samples was done on cytocentrifuge slides, using the P12 monoclonal antibody against the Lewis X antigen. The diagnosis of the presence of urothelial tumor was made if more than 5% of the cells showed a typical red-brown staining. Cytopathologic examination of the third urine specimen was done according to Papanicolaou. Each patient underwent cystoscopy, and biopsies were obtained whenever there was endoscopic evidence of bladder tumors or carcinoma in situ.
RESULTS: Cystoscopy and biopsies revealed transitional cell carcinoma in 32 patients, whereas 69 patients had no evidence of bladder tumors. Immunocytology of one urine sample showed true-positive results in 26 of the 32 patients with bladder tumors, corresponding to a sensitivity of 81.25%. When two samples were examined, a sensitivity of 97% and a specificity of 85.5% were obtained. When the results of cytology and immunocytology were combined, sensitivity reached 100%. High-grade and low-grade transitional cell tumors were detected with equal efficiency.
CONCLUSIONS: The use of P12 monoclonal antibody for evaluation of Lewis X reactivity in cytologic preparations from multiple voided urine specimens can improve the sensitivity of noninvasive detection of bladder cancer. The technique may ultimately replace cystoscopy in monitoring therapeutic response and tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7624989     DOI: 10.1016/s0090-4295(99)80189-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

Review 1.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Telomerase activity detected by quantitative assay in bladder carcinoma and exfoliated cells in urine.

Authors:  R Fedriga; R Gunelli; O Nanni; F Bacci; D Amadori; D Calistri
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

Review 3.  The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder.

Authors:  S W Shelfo; M S Soloway
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

4.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine.

Authors:  A Vlahou; P F Schellhammer; S Mendrinos; K Patel; F I Kondylis; L Gong; S Nasim; G L Wright
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

5.  Development and characterization of a specific IgG monoclonal antibody toward the Lewis x antigen using splenocytes of Schistosoma mansoni-infected mice.

Authors:  Msano Mandalasi; Nelum Dorabawila; David F Smith; Jamie Heimburg-Molinaro; Richard D Cummings; A Kwame Nyame
Journal:  Glycobiology       Date:  2013-03-29       Impact factor: 4.313

6.  Critical evaluation of urinary markers for bladder cancer detection and monitoring.

Authors:  Shahrokh F Shariat; Jose A Karam; Yair Lotan; Pierre I Karakiewizc
Journal:  Rev Urol       Date:  2008

Review 7.  Bladder tumor markers: need, nature and application. 1. Nucleus-based markers.

Authors:  M M Kirollos; S McDermott; R A Bradbrook
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

Review 8.  Bladder tumor markers: need, nature and application. 2. Tumor and tumor-associated antigens.

Authors:  M M Kirollos; S McDermott; R A Bradbrook
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

Review 9.  [Non-invasive urinary diagnosis of bladder cancer. What do we know?].

Authors:  I Kausch; A Böhle
Journal:  Urologe A       Date:  2003-04-11       Impact factor: 0.639

Review 10.  Non-invasive methods of bladder cancer detection.

Authors:  Brian Little
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.